Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 8/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11540203 | 0.98 | CDK8 (0.47) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL13325699 | 0.81 | CDK8 (0.46) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL15060275 | 0.79 | CDK8 (0.44) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL14781567 | 0.77 | CDK8 (0.45) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL9002060 | 0.75 | ROCK1 (0.44) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL30852419 | 0.74 | CDK8 (0.50) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL9002040 | 0.74 | CDK8 (0.40) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| Hydrochloric Acid SCHEMBL9002197 | 0.74 | ROCK1 (0.42) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL11536544 | 0.74 | CDK8 (0.50) | CDK8ROCK1KDRMAP4K2CHEK1 | |
| SCHEMBL10247 | 0.74 | CDK8 (0.53) | CDK8ROCK1KDRMAP4K2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590675-A1 | HETEROCYCLIC SIK INHIBITORS | Pfizer Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2024062360-A1 | HETEROCYCLIC SIK INHIBITORS | PFIZER INC. (US) | 2024-03-28 | — | — | WO | claimed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4590675-A1 | HETEROCYCLIC SIK INHIBITORS | Pfizer Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024062360-A1 | HETEROCYCLIC SIK INHIBITORS | PFIZER INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-2427454-B1 | Phenoxymethyl heterocyclic compounds | ENVIVO PHARMACEUTICALS INC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-4163745-A | ANTIDIABETIC, HYPOGLYCEMIC | PFIZER INC. (US) | 1979-08-07 | — | — | US | disclosed |
| US-4141898-A | Imidazo pyridinium quaternary salts as hypoglycemic agents | PFIZER INC. (US) | 1979-02-27 | — | — | US | disclosed |
| US-4129567-A | IMIDAZOPYRIDINES AND ISOB IDINE | PFIZER INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4097598-A | Quaternary salts as hypoglycemic agents | PFIZER INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4093616-A | PYRROLO(1,2-A)PYRAZINIUM, PYRAZOLO(1,5-A)PYRIDINIUM, 1H-IMIDAZO(2,1-A)ISOQUINOLINIUM, OR IMIDAZO(5,1-A)ISOQUINOLINIUM SALTS | PFIZER INC. (US) | 1978-06-06 | — | — | US | disclosed |
| US-4044015-A | Imidazopyridinium compounds as hypoglycemic agents | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | CDK8 607/4885ROCK1 1018/4885KDR 3871/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | CDK8 837/4885ROCK1 1314/4885KDR 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.